Fermenta Biotech Limited will hold a group and one-to-one investor meeting in Mumbai on June 15, 2026, to discuss its audited financial results for the year ended March 31, 2026. The meeting, scheduled between 10:00 am to 06:00 pm, will be conducted in person through the company's Investor Relations firm, Kaptify Consulting. This interaction allows investors to engage directly with management regarding the FY26 performance.

The company confirmed that the investor presentation and the press release dated May 26, 2026, regarding the financial results have been uploaded on its website and the BSE Limited website. Fermenta Biotech stated that no unpublished price sensitive information (UPSI) will be shared during the meeting. The discussions will be based on publicly available information, and the schedule is subject to changes due to exigencies on the part of the company or investors.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Varadvinayak Khambete, Company Secretary & Head – Legal, signed the intimation on behalf of Fermenta Biotech Limited.

Fermenta Biotech Limited reported a profit after tax of ₹70.3 crore for the financial year ended March 31, 2026, a decrease of 8% from the previous year. The decline reflects a high base effect from one-time real estate income of ₹44.6 crore recorded in FY25, compared to ₹1.6 crore in FY26. Excluding real estate, revenue grew 27% year-on-year to ₹546 crore, driven by strong performance in the Vitamin D3 Human Nutrition segment. The Board of Directors recommended a final dividend of ₹3.75 per share, subject to shareholder approval.

Financial Performance for FY26

Consolidated revenue, including real estate, stood at ₹547.8 crore for FY26, up 14% from the same year-ago period. EBITDA for the year was ₹122.2 crore, a marginal increase of 0.5% year-on-year. On a standalone basis, the net profit was ₹642.84 crore, while consolidated net profit was ₹702.54 crore. The statutory auditors, SRBC & Co. LLP, issued an unmodified opinion on the audited financial results.

Operational Highlights and Exceptional Items

The company recorded exceptional items amounting to ₹69.76 crore for the year. These included a reversal of provisions against receivables amounting to ₹9.07 crore and an expense of ₹2.19 crore recognized towards employee benefit obligations due to the implementation of new Labour Codes. Additionally, a provision of ₹3.1 crore related to semi-finished inventory consumed was reversed in the current quarter. Adjusted for these one-offs and real estate income, underlying profitability showed material improvement aligned with the 44% growth in EBITDA excluding real estate.

Segment and Geographical Performance

The Nutrition Business drove growth, with Vitamin D3 – Human Nutrition revenue rising 28% to ₹292.7 crore and Vitamin D3 – Animal Nutrition increasing 32% to ₹108.5 crore. Green Chemistry Solutions sales more than doubled to ₹15.9 crore. Geographically, India contributed 39% of revenue, while Europe and North America accounted for 30% and 13%, respectively. The German toll manufacturing subsidiary's revenue surged 101% to ₹76.6 crore.